nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—Methotrexate—testicular cancer	0.284	0.436	CbGbCtD
Alprostadil—ABCC5—Cisplatin—testicular cancer	0.28	0.43	CbGbCtD
Alprostadil—ABCC4—Methotrexate—testicular cancer	0.0872	0.134	CbGbCtD
Alprostadil—PTGER2—Ovarian Infertility Genes—DAZL—testicular cancer	0.0318	0.405	CbGpPWpGaD
Alprostadil—Dinoprost Tromethamine—HPGDS—testicular cancer	0.00605	0.565	CrCbGaD
Alprostadil—PTGER2—female gonad—testicular cancer	0.00488	0.0735	CbGeAlD
Alprostadil—PTGER2—G alpha (s) signalling events—INSL3—testicular cancer	0.00468	0.0597	CbGpPWpGaD
Alprostadil—Dinoprostone—HPGDS—testicular cancer	0.00465	0.435	CrCbGaD
Alprostadil—PTGER1—female gonad—testicular cancer	0.00462	0.0697	CbGeAlD
Alprostadil—PTGER2—testis—testicular cancer	0.00433	0.0652	CbGeAlD
Alprostadil—SLCO3A1—seminal vesicle—testicular cancer	0.00429	0.0647	CbGeAlD
Alprostadil—SLCO2A1—seminal vesicle—testicular cancer	0.00425	0.0641	CbGeAlD
Alprostadil—PTGIR—gonad—testicular cancer	0.00351	0.053	CbGeAlD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00345	0.044	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00327	0.0417	CbGpPWpGaD
Alprostadil—PTGIR—G alpha (s) signalling events—INSL3—testicular cancer	0.00316	0.0403	CbGpPWpGaD
Alprostadil—PTGER2—lymph node—testicular cancer	0.00314	0.0473	CbGeAlD
Alprostadil—SLCO3A1—gonad—testicular cancer	0.0031	0.0468	CbGeAlD
Alprostadil—ABCC5—NRF2 pathway—SLC2A6—testicular cancer	0.00288	0.0367	CbGpPWpGaD
Alprostadil—PTGIR—female gonad—testicular cancer	0.00286	0.0431	CbGeAlD
Alprostadil—PTGIR—testis—testicular cancer	0.00253	0.0382	CbGeAlD
Alprostadil—SLCO3A1—female gonad—testicular cancer	0.00252	0.038	CbGeAlD
Alprostadil—SLCO2A1—female gonad—testicular cancer	0.0025	0.0376	CbGeAlD
Alprostadil—ABCC5—female gonad—testicular cancer	0.00228	0.0344	CbGeAlD
Alprostadil—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.00228	0.0291	CbGpPWpGaD
Alprostadil—SLCO3A1—testis—testicular cancer	0.00224	0.0337	CbGeAlD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00223	0.0284	CbGpPWpGaD
Alprostadil—SLCO2A1—testis—testicular cancer	0.00221	0.0334	CbGeAlD
Alprostadil—ABCC5—testis—testicular cancer	0.00203	0.0305	CbGeAlD
Alprostadil—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.00199	0.0254	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0019	0.0242	CbGpPWpGaD
Alprostadil—PTGIR—lymph node—testicular cancer	0.00184	0.0277	CbGeAlD
Alprostadil—SLCO2B1—female gonad—testicular cancer	0.00179	0.0269	CbGeAlD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00175	0.0224	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—INSL3—testicular cancer	0.0017	0.0217	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00166	0.0212	CbGpPWpGaD
Alprostadil—SLCO3A1—lymph node—testicular cancer	0.00162	0.0244	CbGeAlD
Alprostadil—SLCO2A1—lymph node—testicular cancer	0.0016	0.0242	CbGeAlD
Alprostadil—SLCO2B1—testis—testicular cancer	0.00159	0.0239	CbGeAlD
Alprostadil—ABCC4—female gonad—testicular cancer	0.00158	0.0239	CbGeAlD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00151	0.0192	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00151	0.0192	CbGpPWpGaD
Alprostadil—ABCC5—lymph node—testicular cancer	0.00147	0.0221	CbGeAlD
Alprostadil—ABCC4—testis—testicular cancer	0.0014	0.0212	CbGeAlD
Alprostadil—SLCO2B1—lymph node—testicular cancer	0.00115	0.0173	CbGeAlD
Alprostadil—PTGIR—GPCR ligand binding—INSL3—testicular cancer	0.00115	0.0146	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—INSL3—testicular cancer	0.00115	0.0146	CbGpPWpGaD
Alprostadil—ABCC4—lymph node—testicular cancer	0.00102	0.0153	CbGeAlD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000964	0.0123	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—INSL3—testicular cancer	0.00096	0.0122	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000922	0.0118	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—INSL3—testicular cancer	0.000872	0.0111	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—INSL3—testicular cancer	0.000648	0.00827	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—INSL3—testicular cancer	0.000648	0.00827	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000639	0.00815	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—INSL3—testicular cancer	0.000589	0.00751	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—INSL3—testicular cancer	0.000589	0.00751	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—INSL3—testicular cancer	0.000515	0.00657	CbGpPWpGaD
Alprostadil—Abnormal vision—Epirubicin—testicular cancer	0.000372	0.00192	CcSEcCtD
Alprostadil—Sepsis—Epirubicin—testicular cancer	0.000371	0.00191	CcSEcCtD
Alprostadil—Pruritus—Chlorambucil—testicular cancer	0.000368	0.0019	CcSEcCtD
Alprostadil—Cough—Ifosfamide—testicular cancer	0.000368	0.0019	CcSEcCtD
Alprostadil—Thrombocytopenia—Dactinomycin—testicular cancer	0.000368	0.0019	CcSEcCtD
Alprostadil—Convulsion—Ifosfamide—testicular cancer	0.000365	0.00189	CcSEcCtD
Alprostadil—Hypertension—Ifosfamide—testicular cancer	0.000364	0.00188	CcSEcCtD
Alprostadil—Erythema—Cisplatin—testicular cancer	0.000364	0.00188	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—testicular cancer	0.000363	0.00187	CcSEcCtD
Alprostadil—Ecchymosis—Doxorubicin—testicular cancer	0.000357	0.00184	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—testicular cancer	0.000356	0.00184	CcSEcCtD
Alprostadil—Diarrhoea—Chlorambucil—testicular cancer	0.000356	0.00184	CcSEcCtD
Alprostadil—Flushing—Etoposide—testicular cancer	0.000355	0.00183	CcSEcCtD
Alprostadil—Discomfort—Ifosfamide—testicular cancer	0.000355	0.00183	CcSEcCtD
Alprostadil—Muscle spasms—Cisplatin—testicular cancer	0.00035	0.0018	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—INSL3—testicular cancer	0.000348	0.00444	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—INSL3—testicular cancer	0.000348	0.00444	CbGpPWpGaD
Alprostadil—Abnormal vision—Doxorubicin—testicular cancer	0.000345	0.00178	CcSEcCtD
Alprostadil—Pain—Bleomycin—testicular cancer	0.000344	0.00178	CcSEcCtD
Alprostadil—Oedema—Ifosfamide—testicular cancer	0.000344	0.00178	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—testicular cancer	0.000343	0.00177	CcSEcCtD
Alprostadil—Asthenia—Vinblastine—testicular cancer	0.000342	0.00176	CcSEcCtD
Alprostadil—Infection—Ifosfamide—testicular cancer	0.000342	0.00176	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—testicular cancer	0.000342	0.00176	CcSEcCtD
Alprostadil—Lethargy—Methotrexate—testicular cancer	0.000338	0.00174	CcSEcCtD
Alprostadil—Thrombocytopenia—Ifosfamide—testicular cancer	0.000337	0.00174	CcSEcCtD
Alprostadil—Anaemia—Cisplatin—testicular cancer	0.000336	0.00173	CcSEcCtD
Alprostadil—Skin disorder—Ifosfamide—testicular cancer	0.000334	0.00172	CcSEcCtD
Alprostadil—Hyperhidrosis—Ifosfamide—testicular cancer	0.000333	0.00172	CcSEcCtD
Alprostadil—Feeling abnormal—Bleomycin—testicular cancer	0.000332	0.00171	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—testicular cancer	0.00033	0.0017	CcSEcCtD
Alprostadil—Diarrhoea—Vinblastine—testicular cancer	0.000326	0.00168	CcSEcCtD
Alprostadil—Back pain—Etoposide—testicular cancer	0.000322	0.00166	CcSEcCtD
Alprostadil—Hypotension—Ifosfamide—testicular cancer	0.000322	0.00166	CcSEcCtD
Alprostadil—Pain—Dactinomycin—testicular cancer	0.000321	0.00166	CcSEcCtD
Alprostadil—Muscle spasms—Etoposide—testicular cancer	0.00032	0.00165	CcSEcCtD
Alprostadil—Body temperature increased—Bleomycin—testicular cancer	0.000318	0.00164	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—testicular cancer	0.000318	0.00164	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—testicular cancer	0.000316	0.00163	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—testicular cancer	0.000316	0.00163	CcSEcCtD
Alprostadil—Dizziness—Vinblastine—testicular cancer	0.000315	0.00163	CcSEcCtD
Alprostadil—Convulsion—Cisplatin—testicular cancer	0.000315	0.00163	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—testicular cancer	0.00031	0.0016	CcSEcCtD
Alprostadil—Feeling abnormal—Dactinomycin—testicular cancer	0.000309	0.0016	CcSEcCtD
Alprostadil—Nausea—Chlorambucil—testicular cancer	0.000309	0.00159	CcSEcCtD
Alprostadil—Anaemia—Etoposide—testicular cancer	0.000308	0.00159	CcSEcCtD
Alprostadil—Discomfort—Cisplatin—testicular cancer	0.000306	0.00158	CcSEcCtD
Alprostadil—Headache—Vinblastine—testicular cancer	0.000299	0.00154	CcSEcCtD
Alprostadil—Abdominal pain—Dactinomycin—testicular cancer	0.000297	0.00153	CcSEcCtD
Alprostadil—Body temperature increased—Dactinomycin—testicular cancer	0.000297	0.00153	CcSEcCtD
Alprostadil—Oedema—Cisplatin—testicular cancer	0.000297	0.00153	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—testicular cancer	0.000295	0.00152	CcSEcCtD
Alprostadil—Infection—Cisplatin—testicular cancer	0.000295	0.00152	CcSEcCtD
Alprostadil—Pain—Ifosfamide—testicular cancer	0.000294	0.00152	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—testicular cancer	0.000294	0.00152	CcSEcCtD
Alprostadil—Loss of consciousness—Etoposide—testicular cancer	0.000293	0.00151	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—testicular cancer	0.000293	0.00151	CcSEcCtD
Alprostadil—Cough—Etoposide—testicular cancer	0.000291	0.0015	CcSEcCtD
Alprostadil—Thrombocytopenia—Cisplatin—testicular cancer	0.00029	0.0015	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—testicular cancer	0.00029	0.0015	CcSEcCtD
Alprostadil—Tachycardia—Cisplatin—testicular cancer	0.00029	0.00149	CcSEcCtD
Alprostadil—Asthenia—Bleomycin—testicular cancer	0.000289	0.00149	CcSEcCtD
Alprostadil—Convulsion—Etoposide—testicular cancer	0.000289	0.00149	CcSEcCtD
Alprostadil—Skin disorder—Cisplatin—testicular cancer	0.000288	0.00149	CcSEcCtD
Alprostadil—Hypertension—Etoposide—testicular cancer	0.000288	0.00148	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—testicular cancer	0.000287	0.00148	CcSEcCtD
Alprostadil—Hyperhidrosis—Cisplatin—testicular cancer	0.000287	0.00148	CcSEcCtD
Alprostadil—Pruritus—Bleomycin—testicular cancer	0.000285	0.00147	CcSEcCtD
Alprostadil—Feeling abnormal—Ifosfamide—testicular cancer	0.000284	0.00146	CcSEcCtD
Alprostadil—Nausea—Vinblastine—testicular cancer	0.000283	0.00146	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—testicular cancer	0.000282	0.00146	CcSEcCtD
Alprostadil—Discomfort—Etoposide—testicular cancer	0.00028	0.00145	CcSEcCtD
Alprostadil—Hypotension—Cisplatin—testicular cancer	0.000277	0.00143	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—testicular cancer	0.000273	0.00141	CcSEcCtD
Alprostadil—Abdominal pain—Ifosfamide—testicular cancer	0.000272	0.0014	CcSEcCtD
Alprostadil—Body temperature increased—Ifosfamide—testicular cancer	0.000272	0.0014	CcSEcCtD
Alprostadil—Infection—Etoposide—testicular cancer	0.00027	0.00139	CcSEcCtD
Alprostadil—Asthenia—Dactinomycin—testicular cancer	0.000269	0.00139	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—testicular cancer	0.000269	0.00139	CcSEcCtD
Alprostadil—Influenza—Epirubicin—testicular cancer	0.000268	0.00138	CcSEcCtD
Alprostadil—Thrombocytopenia—Etoposide—testicular cancer	0.000266	0.00137	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000266	0.00137	CcSEcCtD
Alprostadil—Tachycardia—Etoposide—testicular cancer	0.000265	0.00137	CcSEcCtD
Alprostadil—Skin disorder—Etoposide—testicular cancer	0.000264	0.00136	CcSEcCtD
Alprostadil—Hyperhidrosis—Etoposide—testicular cancer	0.000263	0.00136	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—testicular cancer	0.000261	0.00135	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—testicular cancer	0.000258	0.00133	CcSEcCtD
Alprostadil—Diarrhoea—Dactinomycin—testicular cancer	0.000257	0.00133	CcSEcCtD
Alprostadil—Hypotension—Etoposide—testicular cancer	0.000254	0.00131	CcSEcCtD
Alprostadil—Rash—Bleomycin—testicular cancer	0.000254	0.00131	CcSEcCtD
Alprostadil—Pain—Cisplatin—testicular cancer	0.000254	0.00131	CcSEcCtD
Alprostadil—Dermatitis—Bleomycin—testicular cancer	0.000254	0.00131	CcSEcCtD
Alprostadil—Renal failure—Methotrexate—testicular cancer	0.000251	0.00129	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000249	0.00128	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—testicular cancer	0.000248	0.00128	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—testicular cancer	0.000248	0.00128	CcSEcCtD
Alprostadil—Asthenia—Ifosfamide—testicular cancer	0.000247	0.00127	CcSEcCtD
Alprostadil—Feeling abnormal—Cisplatin—testicular cancer	0.000244	0.00126	CcSEcCtD
Alprostadil—Pruritus—Ifosfamide—testicular cancer	0.000243	0.00126	CcSEcCtD
Alprostadil—Haematuria—Methotrexate—testicular cancer	0.000243	0.00126	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—testicular cancer	0.000242	0.00125	CcSEcCtD
Alprostadil—Nausea—Bleomycin—testicular cancer	0.000239	0.00123	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—testicular cancer	0.000238	0.00123	CcSEcCtD
Alprostadil—Rash—Dactinomycin—testicular cancer	0.000237	0.00122	CcSEcCtD
Alprostadil—Diarrhoea—Ifosfamide—testicular cancer	0.000235	0.00121	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—testicular cancer	0.000235	0.00121	CcSEcCtD
Alprostadil—Body temperature increased—Cisplatin—testicular cancer	0.000235	0.00121	CcSEcCtD
Alprostadil—Pain—Etoposide—testicular cancer	0.000232	0.0012	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—testicular cancer	0.000232	0.0012	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.00023	0.00119	CcSEcCtD
Alprostadil—Haemoglobin—Methotrexate—testicular cancer	0.00023	0.00119	CcSEcCtD
Alprostadil—Haemorrhage—Methotrexate—testicular cancer	0.000229	0.00118	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—testicular cancer	0.000229	0.00118	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—testicular cancer	0.000228	0.00118	CcSEcCtD
Alprostadil—Dizziness—Ifosfamide—testicular cancer	0.000228	0.00117	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—testicular cancer	0.000227	0.00117	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—testicular cancer	0.000225	0.00116	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—testicular cancer	0.000224	0.00116	CcSEcCtD
Alprostadil—Feeling abnormal—Etoposide—testicular cancer	0.000224	0.00116	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—testicular cancer	0.000224	0.00115	CcSEcCtD
Alprostadil—Nausea—Dactinomycin—testicular cancer	0.000223	0.00115	CcSEcCtD
Alprostadil—Visual impairment—Methotrexate—testicular cancer	0.000221	0.00114	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—testicular cancer	0.000218	0.00113	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—testicular cancer	0.000217	0.00112	CcSEcCtD
Alprostadil—Rash—Ifosfamide—testicular cancer	0.000217	0.00112	CcSEcCtD
Alprostadil—Dermatitis—Ifosfamide—testicular cancer	0.000217	0.00112	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—testicular cancer	0.000216	0.00111	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—testicular cancer	0.000215	0.00111	CcSEcCtD
Alprostadil—Abdominal pain—Etoposide—testicular cancer	0.000215	0.00111	CcSEcCtD
Alprostadil—Body temperature increased—Etoposide—testicular cancer	0.000215	0.00111	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—testicular cancer	0.000215	0.00111	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—testicular cancer	0.000214	0.00111	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—testicular cancer	0.000213	0.0011	CcSEcCtD
Alprostadil—Asthenia—Cisplatin—testicular cancer	0.000213	0.0011	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—testicular cancer	0.000213	0.0011	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—testicular cancer	0.000211	0.00109	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—testicular cancer	0.00021	0.00108	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—testicular cancer	0.000207	0.00107	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—testicular cancer	0.000207	0.00107	CcSEcCtD
Alprostadil—Nausea—Ifosfamide—testicular cancer	0.000204	0.00105	CcSEcCtD
Alprostadil—Diarrhoea—Cisplatin—testicular cancer	0.000203	0.00105	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—testicular cancer	0.000202	0.00104	CcSEcCtD
Alprostadil—Erythema—Methotrexate—testicular cancer	0.000199	0.00103	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—testicular cancer	0.000199	0.00103	CcSEcCtD
Alprostadil—Flushing—Epirubicin—testicular cancer	0.000199	0.00103	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—testicular cancer	0.000199	0.00103	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—testicular cancer	0.000198	0.00102	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—testicular cancer	0.000197	0.00102	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—testicular cancer	0.000197	0.00102	CcSEcCtD
Alprostadil—Asthenia—Etoposide—testicular cancer	0.000195	0.00101	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—testicular cancer	0.000195	0.001	CcSEcCtD
Alprostadil—Back pain—Methotrexate—testicular cancer	0.000193	0.000996	CcSEcCtD
Alprostadil—Pruritus—Etoposide—testicular cancer	0.000192	0.000992	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—testicular cancer	0.000191	0.000987	CcSEcCtD
Alprostadil—Rash—Cisplatin—testicular cancer	0.000187	0.000965	CcSEcCtD
Alprostadil—Dermatitis—Cisplatin—testicular cancer	0.000187	0.000964	CcSEcCtD
Alprostadil—Erythema—Epirubicin—testicular cancer	0.000187	0.000963	CcSEcCtD
Alprostadil—Diarrhoea—Etoposide—testicular cancer	0.000186	0.00096	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—testicular cancer	0.000184	0.000951	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—testicular cancer	0.000184	0.00095	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—testicular cancer	0.000181	0.000936	CcSEcCtD
Alprostadil—Back pain—Epirubicin—testicular cancer	0.000181	0.000932	CcSEcCtD
Alprostadil—Dizziness—Etoposide—testicular cancer	0.00018	0.000927	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—testicular cancer	0.000179	0.000926	CcSEcCtD
Alprostadil—Nausea—Cisplatin—testicular cancer	0.000176	0.000909	CcSEcCtD
Alprostadil—Cough—Methotrexate—testicular cancer	0.000174	0.000898	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—testicular cancer	0.000173	0.000892	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—testicular cancer	0.000173	0.000891	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—testicular cancer	0.000173	0.00089	CcSEcCtD
Alprostadil—Rash—Etoposide—testicular cancer	0.000171	0.000884	CcSEcCtD
Alprostadil—Dermatitis—Etoposide—testicular cancer	0.000171	0.000883	CcSEcCtD
Alprostadil—Headache—Etoposide—testicular cancer	0.00017	0.000879	CcSEcCtD
Alprostadil—Discomfort—Methotrexate—testicular cancer	0.000168	0.000866	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—testicular cancer	0.000168	0.000866	CcSEcCtD
Alprostadil—Syncope—Epirubicin—testicular cancer	0.000167	0.000864	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—testicular cancer	0.000167	0.000862	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—testicular cancer	0.000166	0.000857	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—H2AFZ—testicular cancer	0.000165	0.0021	CbGpPWpGaD
Alprostadil—Loss of consciousness—Epirubicin—testicular cancer	0.000164	0.000847	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—STK11—testicular cancer	0.000164	0.00209	CbGpPWpGaD
Alprostadil—Cough—Epirubicin—testicular cancer	0.000163	0.000841	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—testicular cancer	0.000162	0.000835	CcSEcCtD
Alprostadil—Infection—Methotrexate—testicular cancer	0.000162	0.000835	CcSEcCtD
Alprostadil—Nausea—Etoposide—testicular cancer	0.000161	0.000833	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—testicular cancer	0.000161	0.000832	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—testicular cancer	0.00016	0.000824	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—testicular cancer	0.000159	0.000822	CcSEcCtD
Alprostadil—Skin disorder—Methotrexate—testicular cancer	0.000158	0.000816	CcSEcCtD
Alprostadil—Hyperhidrosis—Methotrexate—testicular cancer	0.000157	0.000812	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—testicular cancer	0.000157	0.00081	CcSEcCtD
Alprostadil—ABCC5—Metabolism—HPGDS—testicular cancer	0.000157	0.002	CbGpPWpGaD
Alprostadil—Dry mouth—Epirubicin—testicular cancer	0.000155	0.000802	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—testicular cancer	0.000155	0.000799	CcSEcCtD
Alprostadil—Oedema—Epirubicin—testicular cancer	0.000152	0.000786	CcSEcCtD
Alprostadil—Hypotension—Methotrexate—testicular cancer	0.000152	0.000785	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—testicular cancer	0.000152	0.000783	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—KITLG—testicular cancer	0.000152	0.00193	CbGpPWpGaD
Alprostadil—Infection—Epirubicin—testicular cancer	0.000151	0.000781	CcSEcCtD
Alprostadil—Cough—Doxorubicin—testicular cancer	0.000151	0.000778	CcSEcCtD
Alprostadil—Shock—Epirubicin—testicular cancer	0.00015	0.000773	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—testicular cancer	0.00015	0.000772	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—testicular cancer	0.000149	0.00077	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—testicular cancer	0.000149	0.000769	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—testicular cancer	0.000149	0.000767	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—testicular cancer	0.000148	0.000764	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—testicular cancer	0.000147	0.00076	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—testicular cancer	0.000145	0.00075	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—testicular cancer	0.000144	0.000742	CcSEcCtD
Alprostadil—Dyspepsia—Methotrexate—testicular cancer	0.000143	0.000739	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—testicular cancer	0.000142	0.000735	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—testicular cancer	0.000141	0.000727	CcSEcCtD
Alprostadil—Infection—Doxorubicin—testicular cancer	0.00014	0.000723	CcSEcCtD
Alprostadil—Pain—Methotrexate—testicular cancer	0.000139	0.000718	CcSEcCtD
Alprostadil—Shock—Doxorubicin—testicular cancer	0.000139	0.000716	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—testicular cancer	0.000138	0.000712	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—testicular cancer	0.000138	0.00071	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—testicular cancer	0.000137	0.000707	CcSEcCtD
Alprostadil—ABCC5—Disease—H2AFZ—testicular cancer	0.000137	0.00174	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Doxorubicin—testicular cancer	0.000136	0.000703	CcSEcCtD
Alprostadil—Feeling abnormal—Methotrexate—testicular cancer	0.000134	0.000692	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—testicular cancer	0.000134	0.000692	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—testicular cancer	0.000132	0.00068	CcSEcCtD
Alprostadil—Pain—Epirubicin—testicular cancer	0.00013	0.000672	CcSEcCtD
Alprostadil—Abdominal pain—Methotrexate—testicular cancer	0.000129	0.000664	CcSEcCtD
Alprostadil—Body temperature increased—Methotrexate—testicular cancer	0.000129	0.000664	CcSEcCtD
Alprostadil—ABCC5—Disease—KITLG—testicular cancer	0.000126	0.0016	CbGpPWpGaD
Alprostadil—Feeling abnormal—Epirubicin—testicular cancer	0.000126	0.000648	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—testicular cancer	0.000124	0.00064	CcSEcCtD
Alprostadil—Pain—Doxorubicin—testicular cancer	0.000121	0.000622	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—testicular cancer	0.00012	0.000621	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—testicular cancer	0.00012	0.000621	CcSEcCtD
Alprostadil—Asthenia—Methotrexate—testicular cancer	0.000117	0.000603	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—testicular cancer	0.000116	0.000599	CcSEcCtD
Alprostadil—Pruritus—Methotrexate—testicular cancer	0.000115	0.000594	CcSEcCtD
Alprostadil—ABCC5—Metabolism—STK11—testicular cancer	0.000114	0.00145	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGFR3—testicular cancer	0.000113	0.00144	CbGpPWpGaD
Alprostadil—Abdominal pain—Doxorubicin—testicular cancer	0.000111	0.000575	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—testicular cancer	0.000111	0.000575	CcSEcCtD
Alprostadil—Diarrhoea—Methotrexate—testicular cancer	0.000111	0.000575	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—H2AFZ—testicular cancer	0.000111	0.00142	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—H2AFZ—testicular cancer	0.000111	0.00142	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STK11—testicular cancer	0.000111	0.00141	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STK11—testicular cancer	0.000111	0.00141	CbGpPWpGaD
Alprostadil—Asthenia—Epirubicin—testicular cancer	0.000109	0.000564	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—testicular cancer	0.000108	0.000556	CcSEcCtD
Alprostadil—Dizziness—Methotrexate—testicular cancer	0.000108	0.000555	CcSEcCtD
Alprostadil—Diarrhoea—Epirubicin—testicular cancer	0.000104	0.000538	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—KIT—testicular cancer	0.000103	0.00132	CbGpPWpGaD
Alprostadil—Rash—Methotrexate—testicular cancer	0.000103	0.00053	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—testicular cancer	0.000103	0.000529	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—KITLG—testicular cancer	0.000102	0.00131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KITLG—testicular cancer	0.000102	0.00131	CbGpPWpGaD
Alprostadil—Headache—Methotrexate—testicular cancer	0.000102	0.000526	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—testicular cancer	0.000101	0.000522	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—testicular cancer	0.000101	0.00052	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—testicular cancer	9.97e-05	0.000515	CcSEcCtD
Alprostadil—Nausea—Methotrexate—testicular cancer	9.67e-05	0.000499	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—testicular cancer	9.65e-05	0.000498	CcSEcCtD
Alprostadil—Rash—Epirubicin—testicular cancer	9.61e-05	0.000496	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—testicular cancer	9.6e-05	0.000495	CcSEcCtD
Alprostadil—Headache—Epirubicin—testicular cancer	9.54e-05	0.000492	CcSEcCtD
Alprostadil—ABCC5—Disease—FGFR3—testicular cancer	9.35e-05	0.00119	CbGpPWpGaD
Alprostadil—Dizziness—Doxorubicin—testicular cancer	9.32e-05	0.000481	CcSEcCtD
Alprostadil—Nausea—Epirubicin—testicular cancer	9.05e-05	0.000467	CcSEcCtD
Alprostadil—Rash—Doxorubicin—testicular cancer	8.89e-05	0.000459	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—testicular cancer	8.88e-05	0.000458	CcSEcCtD
Alprostadil—Headache—Doxorubicin—testicular cancer	8.83e-05	0.000456	CcSEcCtD
Alprostadil—ABCC5—Disease—KIT—testicular cancer	8.58e-05	0.00109	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—testicular cancer	8.37e-05	0.000432	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—FGFR3—testicular cancer	7.61e-05	0.000971	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGFR3—testicular cancer	7.61e-05	0.000971	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KIT—testicular cancer	6.99e-05	0.000891	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KIT—testicular cancer	6.99e-05	0.000891	CbGpPWpGaD
